Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)
NCT ID: NCT02241057
Last Updated: 2017-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2014-09-30
2014-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Comparative Study to Evaluate Two Air-Activated Adhesive Backed Heat Patches
NCT02080143
Safety, Tolerability And On-Body Temperature Of A Disposable Heatwrap Device For The Lower Back
NCT01055262
A Clinical Investigation With BARRIER® EasyWarm®
NCT04813809
Efficacy of Warming Garment in the Perioperative Period With Integrated Chemical Heat Packs to Maintain Normothermia
NCT02905708
Single-Treatment, Study of Percutaneous-Temperature Controlled-RF Electrocoagulation on Axilla Tissue
NCT03107065
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Temperature
Evaluate the temperature profile of the air activated 3-cell patch during 8 hours of wear
Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)
Temperature Probe
Adhesion
Evaluate the adhesion with and without the presence of a temperature probe
Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)
Temperature Probe
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects 18-75 years old of either sex.
* Are of any skin type or race, providing the skin pigmentation will allow discernment of erythema;
* Subjects who are in good general health.
* Subjects who are willing and able to have the test products applied as directed, and comply with study instructions.
* Participants must be willing to restrict their activity for the 8 hour patch wear time.
* All participants agree to wear a t-shirt provided by the site for the entire 8 hour patch wear time.
Exclusion Criteria
* Subjects who are pregnant.
* Subject with excessive hair at the application sites, scar tissue, tattoo, or coloration that would interfere with placement of test product or skin assessment.
* Subjects with diabetes, rheumatoid arthritis, poor circulation or have any clinically significant chronic illness.
* Subjects with active dermatitis (including sunburn) in the treatment area, or other visible dermatological disease which, in the investigator's opinion, might interfere with the response to the test products or interfere with the skin assessments associated with the test products.
* Have history of significant dermatologic cancers (eg, melanoma, squamous cell carcinoma).
* Subjects who have used topical dermatological products in the application area within 24 hours prior to the test product application.
* Subject using a concomitant medication that, in the investigator's opinion, could interfere with the interpretation of study results. Examples of such drugs include non-steroidal anti-inflammatory drugs (NSAIDs, e.g., aspirin), topical or systemic corticosteroids, and cold/cough products containing antihistamines and/or either phentolamine, pseudoephedrine or phenylpropanolamine.
* Subjects who have received an investigational medication or device within 30 days prior to enrolment into this study.
* Subjects who are currently participating in an investigational study.
* Subject who are known to be noncompliant or are unlikely to comply with the requirements of the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in the opinion of the investigator.
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chattem, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ellen Bonagua, MD
Role: PRINCIPAL_INVESTIGATOR
Chattem, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wilkins Research
Chattanooga, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.